SCHEMBL1765049

SCHEMBL1765049

O=C1CN(C(=O)c2cc(-c3cc(F)cc(C(F)(F)F)c3)n(-c3cccc(Cl)c3)n2)CN1

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SLC5A1 P13866 11/20 0.44
PPP1CA P62136 1/20 0.42
MALT1 Q9UDY8 2/20 0.39
CCKAR P32238 1/20 0.39
PTGS2 P35354 2/20 0.39
PTGS1 P23219 1/20 0.39
MGLL Q99685 1/20 0.39
NPY5R Q15761 1/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1765519 0.95 PPP1CA (0.45) SLC5A1PPP1CAMALT1CCKARPTGS2
SCHEMBL1765529 0.92 PPP1CA (0.47) SLC5A1PPP1CAMALT1CCKARPTGS2
SCHEMBL1765282 0.91 MEN1 (0.42) SLC5A1PPP1CAMALT1PTGS2PTGS1
SCHEMBL1765351 0.90 PPP1CA (0.46) SLC5A1PPP1CAMALT1CCKARPTGS2
SCHEMBL14995616 0.88 PPP1CA (0.42) SLC5A1PPP1CAMALT1CCKARPTGS2
SCHEMBL1765488 0.88 PTGS2 (0.45) SLC5A1PPP1CACCKARPTGS2PTGS1
SCHEMBL1765378 0.88 CCKAR (0.46) SLC5A1PPP1CAMALT1CCKARPTGS2
SCHEMBL1764968 0.85 KDM1A (0.44) SLC5A1PPP1CAMALT1CCKARPTGS2
SCHEMBL1764979 0.85 CCKAR (0.51) SLC5A1PPP1CAMALT1CCKARPTGS2
SCHEMBL1765086 0.85 PPP1CA (0.45) SLC5A1PPP1CAMALT1CCKARPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE TPMT, PAICS, THPO SLC5A1 2409/4885PPP1CA 1664/4885MALT1 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.